25 XP   0   0   10

Achilles Therapeutics PLC ADR
Buy, Hold or Sell?

Let's analyse Achilles Therapeutics PLC ADR together

PenkeI guess you are interested in Achilles Therapeutics PLC ADR. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Achilles Therapeutics PLC ADR. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Achilles Therapeutics PLC ADR

I send you an email if I find something interesting about Achilles Therapeutics PLC ADR.

Quick analysis of Achilles Therapeutics PLC ADR (30 sec.)










What can you expect buying and holding a share of Achilles Therapeutics PLC ADR? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$3.49
Expected worth in 1 year
$2.44
How sure are you?
22.7%

+ What do you gain per year?

Total Gains per Share
$-1.05
Return On Investment
-135.5%

For what price can you sell your share?

Current Price per Share
$0.77
Expected price per share
$0.7402 - $0.85
How sure are you?
50%

1. Valuation of Achilles Therapeutics PLC ADR (5 min.)




Live pricePrice per Share (EOD)

$0.77

Intrinsic Value Per Share

$-2.23 - $-2.20

Total Value Per Share

$1.26 - $1.29

2. Growth of Achilles Therapeutics PLC ADR (5 min.)




Is Achilles Therapeutics PLC ADR growing?

Current yearPrevious yearGrowGrow %
How rich?$142.3m$204.1m-$51m-33.4%

How much money is Achilles Therapeutics PLC ADR making?

Current yearPrevious yearGrowGrow %
Making money-$17.7m-$17.8m$93.9k0.5%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Achilles Therapeutics PLC ADR (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#313 / 1010

Most Revenue
#901 / 1010

Most Profit
#671 / 1010

Most Efficient
#342 / 1010

What can you expect buying and holding a share of Achilles Therapeutics PLC ADR? (5 min.)

Welcome investor! Achilles Therapeutics PLC ADR's management wants to use your money to grow the business. In return you get a share of Achilles Therapeutics PLC ADR.

What can you expect buying and holding a share of Achilles Therapeutics PLC ADR?

First you should know what it really means to hold a share of Achilles Therapeutics PLC ADR. And how you can make/lose money.

Speculation

The Price per Share of Achilles Therapeutics PLC ADR is $0.7744. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Achilles Therapeutics PLC ADR.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Achilles Therapeutics PLC ADR, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.49. Based on the TTM, the Book Value Change Per Share is $-0.26 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.50 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Achilles Therapeutics PLC ADR.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.46-59.5%-0.38-49.0%-0.43-55.9%-0.32-41.0%-0.30-38.2%
Usd Book Value Change Per Share1.69217.9%-0.26-33.9%-0.50-64.3%0.1418.5%0.1620.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share1.69217.9%-0.26-33.9%-0.50-64.3%0.1418.5%0.1620.5%
Usd Price Per Share1.25-1.00-1.66-2.64-2.40-
Price to Earnings Ratio-0.68--0.69--1.07--1.81--1.64-
Price-to-Total Gains Ratio0.74--1.23--4.00--9.13--9.13-
Price to Book Ratio0.36-0.33-0.32-0.49-0.45-
Price-to-Total Gains Ratio0.74--1.23--4.00--9.13--9.13-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.7744
Number of shares1291
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.260.14
Usd Total Gains Per Share-0.260.14
Gains per Quarter (1291 shares)-338.73185.23
Gains per Year (1291 shares)-1,354.92740.94
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1355-13650741731
20-2710-2720014821472
30-4065-4075022232213
40-5420-5430029642954
50-6775-6785037053695
60-8129-8140044464436
70-9484-9495051875177
80-10839-10850059285918
90-12194-12205066686659
100-13549-13560074097400

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.022.00.00.0%0.022.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%4.011.05.020.0%5.011.06.022.7%5.011.06.022.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.022.00.0%0.00.022.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%4.011.05.020.0%5.011.06.022.7%5.011.06.022.7%

Fundamentals of Achilles Therapeutics PLC ADR

About Achilles Therapeutics PLC ADR

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Fundamental data was last updated by Penke on 2024-04-10 23:27:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Achilles Therapeutics PLC ADR.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Achilles Therapeutics PLC ADR earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Achilles Therapeutics PLC ADR to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Achilles Therapeutics PLC ADR:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--216.8%+216.8%
YOY--282.3%+282.3%
5Y--436.8%+436.8%
10Y--597.3%+597.3%
1.1.2. Return on Assets

Shows how efficient Achilles Therapeutics PLC ADR is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Achilles Therapeutics PLC ADR to the Biotechnology industry mean.
  • -11.6% Return on Assets means that Achilles Therapeutics PLC ADR generated $-0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Achilles Therapeutics PLC ADR:

  • The MRQ is -11.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -10.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.6%TTM-10.3%-1.3%
TTM-10.3%YOY-7.9%-2.4%
TTM-10.3%5Y-9.2%-1.1%
5Y-9.2%10Y-9.6%+0.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.6%-13.3%+1.7%
TTM-10.3%-12.8%+2.5%
YOY-7.9%-11.6%+3.7%
5Y-9.2%-13.8%+4.6%
10Y-9.6%-15.6%+6.0%
1.1.3. Return on Equity

Shows how efficient Achilles Therapeutics PLC ADR is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Achilles Therapeutics PLC ADR to the Biotechnology industry mean.
  • -13.2% Return on Equity means Achilles Therapeutics PLC ADR generated $-0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Achilles Therapeutics PLC ADR:

  • The MRQ is -13.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -11.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.2%TTM-11.7%-1.5%
TTM-11.7%YOY-8.8%-2.9%
TTM-11.7%5Y-10.3%-1.4%
5Y-10.3%10Y-10.0%-0.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.2%-16.9%+3.7%
TTM-11.7%-16.1%+4.4%
YOY-8.8%-14.9%+6.1%
5Y-10.3%-19.3%+9.0%
10Y-10.0%-20.1%+10.1%

1.2. Operating Efficiency of Achilles Therapeutics PLC ADR.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Achilles Therapeutics PLC ADR is operating .

  • Measures how much profit Achilles Therapeutics PLC ADR makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Achilles Therapeutics PLC ADR to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Achilles Therapeutics PLC ADR:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM--238.5%+238.5%
YOY--288.4%+288.4%
5Y--486.2%+486.2%
10Y--628.4%+628.4%
1.2.2. Operating Ratio

Measures how efficient Achilles Therapeutics PLC ADR is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Achilles Therapeutics PLC ADR:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM-3.310-3.310
YOY-3.838-3.838
5Y-5.679-5.679
10Y-7.823-7.823

1.3. Liquidity of Achilles Therapeutics PLC ADR.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Achilles Therapeutics PLC ADR is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 8.57 means the company has $8.57 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Achilles Therapeutics PLC ADR:

  • The MRQ is 8.569. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.714. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.569TTM8.714-0.145
TTM8.714YOY10.782-2.069
TTM8.7145Y13.273-4.559
5Y13.27310Y14.495-1.223
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.5693.863+4.706
TTM8.7144.169+4.545
YOY10.7825.337+5.445
5Y13.2736.122+7.151
10Y14.4956.434+8.061
1.3.2. Quick Ratio

Measures if Achilles Therapeutics PLC ADR is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Achilles Therapeutics PLC ADR to the Biotechnology industry mean.
  • A Quick Ratio of 8.35 means the company can pay off $8.35 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Achilles Therapeutics PLC ADR:

  • The MRQ is 8.348. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.326. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ8.348TTM6.326+2.022
TTM6.326YOY10.091-3.764
TTM6.3265Y12.484-6.158
5Y12.48410Y12.605-0.121
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.3483.504+4.844
TTM6.3263.991+2.335
YOY10.0915.371+4.720
5Y12.4846.088+6.396
10Y12.6056.395+6.210

1.4. Solvency of Achilles Therapeutics PLC ADR.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Achilles Therapeutics PLC ADR assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Achilles Therapeutics PLC ADR to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12 means that Achilles Therapeutics PLC ADR assets are financed with 11.8% credit (debt) and the remaining percentage (100% - 11.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Achilles Therapeutics PLC ADR:

  • The MRQ is 0.118. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.121. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.118TTM0.121-0.002
TTM0.121YOY0.106+0.015
TTM0.1215Y0.106+0.015
5Y0.10610Y0.100+0.006
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1180.339-0.221
TTM0.1210.337-0.216
YOY0.1060.271-0.165
5Y0.1060.368-0.262
10Y0.1000.388-0.288
1.4.2. Debt to Equity Ratio

Measures if Achilles Therapeutics PLC ADR is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Achilles Therapeutics PLC ADR to the Biotechnology industry mean.
  • A Debt to Equity ratio of 13.4% means that company has $0.13 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Achilles Therapeutics PLC ADR:

  • The MRQ is 0.134. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.137. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.134TTM0.137-0.003
TTM0.137YOY0.119+0.019
TTM0.1375Y0.120+0.017
5Y0.12010Y0.111+0.009
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1340.392-0.258
TTM0.1370.403-0.266
YOY0.1190.335-0.216
5Y0.1200.427-0.307
10Y0.1110.461-0.350

2. Market Valuation of Achilles Therapeutics PLC ADR

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Achilles Therapeutics PLC ADR generates.

  • Above 15 is considered overpriced but always compare Achilles Therapeutics PLC ADR to the Biotechnology industry mean.
  • A PE ratio of -0.68 means the investor is paying $-0.68 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Achilles Therapeutics PLC ADR:

  • The EOD is -0.420. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.678. Based on the earnings, the company is expensive. -2
  • The TTM is -0.687. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.420MRQ-0.678+0.258
MRQ-0.678TTM-0.687+0.009
TTM-0.687YOY-1.073+0.387
TTM-0.6875Y-1.807+1.120
5Y-1.80710Y-1.643-0.164
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.420-2.300+1.880
MRQ-0.678-2.656+1.978
TTM-0.687-2.718+2.031
YOY-1.073-4.145+3.072
5Y-1.807-6.258+4.451
10Y-1.643-6.315+4.672
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Achilles Therapeutics PLC ADR:

  • The EOD is -0.553. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.893. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -132.491. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.553MRQ-0.893+0.340
MRQ-0.893TTM-132.491+131.598
TTM-132.491YOY-134.968+2.478
TTM-132.4915Y-54.772-77.719
5Y-54.77210Y-49.792-4.979
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.553-2.974+2.421
MRQ-0.893-3.306+2.413
TTM-132.491-3.508-128.983
YOY-134.968-5.613-129.355
5Y-54.772-8.378-46.394
10Y-49.792-8.873-40.919
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Achilles Therapeutics PLC ADR is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.36 means the investor is paying $0.36 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Achilles Therapeutics PLC ADR:

  • The EOD is 0.222. Based on the equity, the company is cheap. +2
  • The MRQ is 0.358. Based on the equity, the company is cheap. +2
  • The TTM is 0.329. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.222MRQ0.358-0.136
MRQ0.358TTM0.329+0.029
TTM0.329YOY0.324+0.005
TTM0.3295Y0.490-0.162
5Y0.49010Y0.446+0.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.2221.914-1.692
MRQ0.3582.116-1.758
TTM0.3292.097-1.768
YOY0.3242.881-2.557
5Y0.4903.550-3.060
10Y0.4463.936-3.490
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Achilles Therapeutics PLC ADR.

3.1. Institutions holding Achilles Therapeutics PLC ADR

Institutions are holding 53.415% of the shares of Achilles Therapeutics PLC ADR.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Syncona Portfolio Ltd.27.18526.24811108690900
2023-12-31FCPM III SERVICES BV5.86040.6267239005023900500
2023-12-31Artal Group S A5.53020.0667225537500
2023-12-31Baker Bros Advisors LP5.15610.02132102792-454357-17.7681
2023-09-30Redmile Group, LLC3.9430.0696160808900
2023-09-30Point72 Asset Management, L.P.3.46670.0038141380900
2023-12-31Renaissance Technologies Corp1.22350.00074989956146714.0487
2023-12-31Vestal Point Capital LP0.2650.01021080831080830
2023-12-31Forefront Analytics, LLC0.1870.033576269-1900-2.4306
2023-09-30Citadel Advisors Llc0.1413057626-9217-13.789
2023-12-31Virtu Financial LLC0.09710.002839593395930
2023-12-31Millennium Management LLC0.07590309491467190.1278
2023-12-31Bank of America Corp0.0554022592-50650-69.1543
2023-12-31Geode Capital Management, LLC0.052902159000
2023-12-31TWO SIGMA SECURITIES, LLC0.03560.000114539145390
2023-12-31Global Retirement Partners, LLC.0.00740.0001300030000
2023-12-31JPMorgan Chase & Co0.0024098900
2023-12-31Qube Research & Technologies0.000207300
2023-12-31Royal Bank of Canada0.000103500
2023-12-31Morgan Stanley - Brokerage Accounts0020-50000-99.96
Total 53.28547.083621731377+2065279+9.5%

3.2. Funds holding Achilles Therapeutics PLC ADR

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Forefront Tiresias Strategy0.17231.393170269-1900-2.6327
2024-02-29Fidelity Nasdaq Composite Index0.05290.00022159000
2024-02-29LUX IM Global Medtech HX0.04390.01311790000
Total 0.26911.4064109759-1900-1.7%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Achilles Therapeutics PLC ADR compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.687-0.262+116%-0.498+130%0.143+1076%0.159+963%
Book Value Per Share--3.4913.330+5%5.005-30%3.866-10%3.571-2%
Current Ratio--8.5698.714-2%10.782-21%13.273-35%14.495-41%
Debt To Asset Ratio--0.1180.121-2%0.106+11%0.106+12%0.100+19%
Debt To Equity Ratio--0.1340.137-2%0.119+13%0.120+12%0.111+21%
Dividend Per Share----0%-0%-0%-0%
Eps---0.461-0.380-18%-0.433-6%-0.317-31%-0.296-36%
Free Cash Flow Per Share---0.350-0.126-64%-0.274-22%-0.260-26%-0.244-30%
Free Cash Flow To Equity Per Share---0.350-0.126-64%-0.274-22%0.239-246%0.261-234%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---2.202--------
Intrinsic Value_10Y_min---2.231--------
Intrinsic Value_1Y_max---0.979--------
Intrinsic Value_1Y_min---0.962--------
Intrinsic Value_3Y_max---2.363--------
Intrinsic Value_3Y_min---2.267--------
Intrinsic Value_5Y_max---3.050--------
Intrinsic Value_5Y_min---2.881--------
Market Cap31582277.760-61%50978625.00049201640.952+4%67674124.688-25%109182374.728-53%99256704.298-49%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio0.222-61%0.3580.329+9%0.324+11%0.490-27%0.446-20%
Pe Ratio-0.420+38%-0.678-0.687+1%-1.073+58%-1.807+166%-1.643+142%
Price Per Share0.774-61%1.2500.999+25%1.659-25%2.636-53%2.396-48%
Price To Free Cash Flow Ratio-0.553+38%-0.893-132.491+14736%-134.968+15013%-54.772+6033%-49.792+5476%
Price To Total Gains Ratio0.459-61%0.741-1.235+267%-4.001+640%-9.135+1333%-9.135+1333%
Quick Ratio--8.3486.326+32%10.091-17%12.484-33%12.605-34%
Return On Assets---0.116-0.103-11%-0.079-32%-0.092-21%-0.096-18%
Return On Equity---0.132-0.117-11%-0.088-33%-0.103-22%-0.100-24%
Total Gains Per Share--1.687-0.262+116%-0.498+130%0.143+1076%0.159+963%
Usd Book Value--142369000.000153016500.000-7%204104750.000-30%161101100.000-12%148758909.091-4%
Usd Book Value Change Per Share--1.687-0.262+116%-0.498+130%0.143+1076%0.159+963%
Usd Book Value Per Share--3.4913.330+5%5.005-30%3.866-10%3.571-2%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.461-0.380-18%-0.433-6%-0.317-31%-0.296-36%
Usd Free Cash Flow---14271100.000-6877893.000-52%-11193260.500-22%-10929543.200-23%-10278766.545-28%
Usd Free Cash Flow Per Share---0.350-0.126-64%-0.274-22%-0.260-26%-0.244-30%
Usd Free Cash Flow To Equity Per Share---0.350-0.126-64%-0.274-22%0.239-246%0.261-234%
Usd Market Cap31582277.760-61%50978625.00049201640.952+4%67674124.688-25%109182374.728-53%99256704.298-49%
Usd Price Per Share0.774-61%1.2500.999+25%1.659-25%2.636-53%2.396-48%
Usd Profit---18792063.000-17737765.750-6%-17831750.000-5%-13461290.650-28%-12555491.500-33%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share--1.687-0.262+116%-0.498+130%0.143+1076%0.159+963%
 EOD+2 -6MRQTTM+13 -16YOY+6 -235Y+7 -2210Y+7 -22

4.2. Fundamental Score

Let's check the fundamental score of Achilles Therapeutics PLC ADR based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.420
Price to Book Ratio (EOD)Between0-10.222
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than18.348
Current Ratio (MRQ)Greater than18.569
Debt to Asset Ratio (MRQ)Less than10.118
Debt to Equity Ratio (MRQ)Less than10.134
Return on Equity (MRQ)Greater than0.15-0.132
Return on Assets (MRQ)Greater than0.05-0.116
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Achilles Therapeutics PLC ADR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.770
Ma 20Greater thanMa 500.899
Ma 50Greater thanMa 1001.105
Ma 100Greater thanMa 2000.998
OpenGreater thanClose0.798
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets161,456
Total Liabilities19,087
Total Stockholder Equity142,369
 As reported
Total Liabilities 19,087
Total Stockholder Equity+ 142,369
Total Assets = 161,456

Assets

Total Assets161,456
Total Current Assets145,633
Long-term Assets15,823
Total Current Assets
Cash And Cash Equivalents 131,539
Net Receivables 10,351
Inventory 0
Other Current Assets 3,743
Total Current Assets  (as reported)145,633
Total Current Assets  (calculated)145,633
+/-0
Long-term Assets
Property Plant Equipment 13,543
Long-term Assets Other 2,206
Long-term Assets  (as reported)15,823
Long-term Assets  (calculated)15,749
+/- 74

Liabilities & Shareholders' Equity

Total Current Liabilities16,996
Long-term Liabilities2,091
Total Stockholder Equity142,369
Total Current Liabilities
Short-term Debt 3,539
Other Current Liabilities 13,457
Total Current Liabilities  (as reported)16,996
Total Current Liabilities  (calculated)16,996
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)2,091
Long-term Liabilities  (calculated)0
+/- 2,091
Total Stockholder Equity
Common Stock182
Retained Earnings -259,952
Accumulated Other Comprehensive Income -13,071
Other Stockholders Equity 415,210
Total Stockholder Equity (as reported)142,369
Total Stockholder Equity (calculated)142,369
+/-0
Other
Cash and Short Term Investments 131,539
Common Stock Shares Outstanding 40,187
Liabilities and Stockholders Equity 161,456
Net Debt -126,924
Net Working Capital 128,637
Short Long Term Debt Total 4,615



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-31
> Total Assets 
26,301
26,301
26,301
26,301
54,730
54,730
54,730
54,730
218,918
206,103
353,490
329,999
317,106
292,190
257,718
227,350
220,358
207,635
197,907
175,338
161,456
161,456
161,456161,456175,338197,907207,635220,358227,350257,718292,190317,106329,999353,490206,103218,91854,73054,73054,73054,73026,30126,30126,30126,301
   > Total Current Assets 
25,765
25,765
25,765
25,765
46,949
46,949
46,949
46,949
187,797
173,320
320,402
298,276
284,749
259,049
227,580
198,687
196,580
185,262
175,210
155,492
145,633
145,633
145,633145,633155,492175,210185,262196,580198,687227,580259,049284,749298,276320,402173,320187,79746,94946,94946,94946,94925,76525,76525,76525,765
       Cash And Cash Equivalents 
24,399
24,399
24,399
24,399
44,462
44,462
44,462
44,462
177,849
159,262
299,317
281,875
266,319
236,931
201,595
179,890
173,338
158,460
143,711
140,138
131,539
131,539
131,539131,539140,138143,711158,460173,338179,890201,595236,931266,319281,875299,317159,262177,84944,46244,46244,46244,46224,39924,39924,39924,399
       Net Receivables 
1,122
1,122
1,122
1,122
1,835
1,835
1,835
1,835
7,339
9,056
11,963
8,293
11,173
14,459
17,131
10,709
16,003
0
23,030
9,598
0
10,351
10,35109,59823,030016,00310,70917,13114,45911,1738,29311,9639,0567,3391,8351,8351,8351,8351,1221,1221,1221,122
       Other Current Assets 
0
245
245
245
652
652
652
652
851
1,083
1,021
1,836
2,124
3,405
2,891
18,797
2,615
26,802
31,499
15,354
1,979
3,743
3,7431,97915,35431,49926,8022,61518,7972,8913,4052,1241,8361,0211,0838516526526526522452452450
   > Long-term Assets 
536
536
536
536
7,780
7,780
7,780
7,780
31,121
32,783
33,088
31,723
32,357
33,141
30,138
28,663
23,778
22,373
22,697
19,846
15,823
15,823
15,82315,82319,84622,69722,37323,77828,66330,13833,14132,35731,72333,08832,78331,1217,7807,7807,7807,780536536536536
       Property Plant Equipment 
528
528
528
528
7,027
7,027
7,027
7,027
28,109
29,634
29,847
28,316
28,791
29,446
27,096
25,891
20,480
19,016
19,322
16,661
13,543
13,543
13,54313,54316,66119,32219,01620,48025,89127,09629,44628,79128,31629,84729,63428,1097,0277,0277,0277,027528528528528
       Long-term Assets Other 
9
9
9
9
752
752
752
752
3,008
3,145
3,237
3,403
3,540
3,669
3,016
2,746
3,047
3,172
3,190
3,000
2,239
2,206
2,2062,2393,0003,1903,1723,0472,7463,0163,6693,5403,4033,2373,1453,0087527527527529999
> Total Liabilities 
964
964
964
964
7,387
7,387
7,387
7,387
29,546
27,050
29,516
24,890
27,578
25,735
26,130
24,734
23,314
22,464
24,064
21,853
19,087
19,087
19,08719,08721,85324,06422,46423,31424,73426,13025,73527,57824,89029,51627,05029,5467,3877,3877,3877,387964964964964
   > Total Current Liabilities 
964
964
964
964
4,156
4,156
4,156
4,156
16,623
15,062
18,613
15,366
19,110
17,852
19,869
19,056
17,993
17,947
19,118
18,181
16,996
16,996
16,99616,99618,18119,11817,94717,99319,05619,86917,85219,11015,36618,61315,06216,6234,1564,1564,1564,156964964964964
       Short-term Debt 
0
0
0
0
0
0
0
0
3,712
4,610
4,660
4,398
4,482
4,670
4,480
4,036
4,188
4,038
4,656
4,620
0
3,539
3,53904,6204,6564,0384,1884,0364,4804,6704,4824,3984,6604,6103,71200000000
       Accounts payable 
0
226
226
226
1,579
1,579
1,579
1,579
6,314
1,787
6,055
2,460
3,722
4,036
6,651
7,516
5,187
7,650
6,886
5,352
5,629
0
05,6295,3526,8867,6505,1877,5166,6514,0363,7222,4606,0551,7876,3141,5791,5791,5791,5792262262260
       Other Current Liabilities 
0
739
739
739
2,577
2,577
2,577
2,577
1,370
1,249
1,602
1,918
1,268
9,146
8,738
7,504
8,618
6,259
7,576
8,209
850
13,457
13,4578508,2097,5766,2598,6187,5048,7389,1461,2681,9181,6021,2491,3702,5772,5772,5772,5777397397390
   > Long-term Liabilities 
0
226
226
226
3,231
3,231
3,231
3,231
12,923
11,988
10,903
9,524
8,468
7,883
6,261
5,678
5,321
4,517
4,946
3,672
2,091
2,091
2,0912,0913,6724,9464,5175,3215,6786,2617,8838,4689,52410,90311,98812,9233,2313,2313,2313,2312262262260
       Other Liabilities 
0
0
0
0
0
0
0
429
652
659
659
643
691
671
621
726
933
0
974
941
0
0
0094197409337266216716916436596596524290000000
> Total Stockholder Equity
0
25,337
25,337
25,337
47,343
47,343
47,343
47,343
189,372
179,053
323,974
305,109
289,528
266,455
231,588
202,616
197,044
185,171
173,843
153,485
142,369
142,369
142,369142,369153,485173,843185,171197,044202,616231,588266,455289,528305,109323,974179,053189,37247,34347,34347,34347,34325,33725,33725,3370
   Common Stock
0
4
4
4
6
6
6
6
25
6
54
54
54
54
54
54
54
54
54
54
0
182
18205454545454545454545462566664440
   Retained Earnings Total Equity0000000000000000000000
   Accumulated Other Comprehensive Income 
-137
-137
-137
-137
-346
-346
-346
-346
12,322
14,385
13,460
5,750
6,636
-1,041
-20,343
-38,490
-21,695
-17,718
-13,901
-19,190
0
-13,071
-13,0710-19,190-13,901-17,718-21,695-38,490-20,343-1,0416,6365,75013,46014,38512,322-346-346-346-346-137-137-137-137
   Capital Surplus 0000000000000000000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 
0
31,674
31,674
31,674
62,186
62,186
62,186
62,186
234,903
236,305
398,393
400,058
401,949
403,780
405,504
407,283
408,972
410,628
412,329
413,943
0
415,210
415,2100413,943412,329410,628408,972407,283405,504403,780401,949400,058398,393236,305234,90362,18662,18662,18662,18631,67431,67431,6740



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-4,731
Gross Profit-4,731-4,731
 
Operating Income (+$)
Gross Profit-4,731
Operating Expense-80,252
Operating Income-84,983-84,983
 
Operating Expense (+$)
Research Development67,908
Selling General Administrative17,345
Selling And Marketing Expenses0
Operating Expense80,25285,253
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-84,983
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-78,879-91,088
EBIT - interestExpense = -84,983
-78,879
-69,935
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-84,983-78,879
Earnings Before Interest and Taxes (EBITDA)-80,252
 
After tax Income (+$)
Income Before Tax-78,879
Tax Provision-27
Net Income From Continuing Ops-75,091-78,906
Net Income-69,935
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses84,983
Total Other Income/Expenses Net6,1050
 

Technical Analysis of Achilles Therapeutics PLC ADR
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Achilles Therapeutics PLC ADR. The general trend of Achilles Therapeutics PLC ADR is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Achilles Therapeutics PLC ADR's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Achilles Therapeutics PLC ADR.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.79 < 0.8 < 0.85.

The bearish price targets are: 0.75 > 0.7402.

Tweet this
Achilles Therapeutics PLC ADR Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Achilles Therapeutics PLC ADR. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Achilles Therapeutics PLC ADR Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Achilles Therapeutics PLC ADR. The current macd is -0.09749589.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Achilles Therapeutics PLC ADR price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Achilles Therapeutics PLC ADR. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Achilles Therapeutics PLC ADR price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Achilles Therapeutics PLC ADR Daily Moving Average Convergence/Divergence (MACD) ChartAchilles Therapeutics PLC ADR Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Achilles Therapeutics PLC ADR. The current adx is 34.10.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Achilles Therapeutics PLC ADR shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Achilles Therapeutics PLC ADR Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Achilles Therapeutics PLC ADR. The current sar is 0.8332.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Achilles Therapeutics PLC ADR Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Achilles Therapeutics PLC ADR. The current rsi is 29.77. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Achilles Therapeutics PLC ADR Daily Relative Strength Index (RSI) ChartAchilles Therapeutics PLC ADR Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Achilles Therapeutics PLC ADR. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Achilles Therapeutics PLC ADR price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Achilles Therapeutics PLC ADR Daily Stochastic Oscillator ChartAchilles Therapeutics PLC ADR Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Achilles Therapeutics PLC ADR. The current cci is -68.50447967.

Achilles Therapeutics PLC ADR Daily Commodity Channel Index (CCI) ChartAchilles Therapeutics PLC ADR Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Achilles Therapeutics PLC ADR. The current cmo is -51.34636615.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Achilles Therapeutics PLC ADR Daily Chande Momentum Oscillator (CMO) ChartAchilles Therapeutics PLC ADR Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Achilles Therapeutics PLC ADR. The current willr is -72.25806452.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Achilles Therapeutics PLC ADR is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Achilles Therapeutics PLC ADR Daily Williams %R ChartAchilles Therapeutics PLC ADR Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Achilles Therapeutics PLC ADR.

Achilles Therapeutics PLC ADR Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Achilles Therapeutics PLC ADR. The current atr is 0.07422392.

Achilles Therapeutics PLC ADR Daily Average True Range (ATR) ChartAchilles Therapeutics PLC ADR Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Achilles Therapeutics PLC ADR. The current obv is 18,752,975.

Achilles Therapeutics PLC ADR Daily On-Balance Volume (OBV) ChartAchilles Therapeutics PLC ADR Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Achilles Therapeutics PLC ADR. The current mfi is 25.27.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Achilles Therapeutics PLC ADR Daily Money Flow Index (MFI) ChartAchilles Therapeutics PLC ADR Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Achilles Therapeutics PLC ADR.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-24MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside

6.3. Candlestick Patterns

Achilles Therapeutics PLC ADR Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Achilles Therapeutics PLC ADR based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.770
Ma 20Greater thanMa 500.899
Ma 50Greater thanMa 1001.105
Ma 100Greater thanMa 2000.998
OpenGreater thanClose0.798
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Achilles Therapeutics PLC ADR with someone you think should read this too:
  • Are you bullish or bearish on Achilles Therapeutics PLC ADR? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Achilles Therapeutics PLC ADR? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Achilles Therapeutics PLC ADR

I send you an email if I find something interesting about Achilles Therapeutics PLC ADR.


Comments

How you think about this?

Leave a comment

Stay informed about Achilles Therapeutics PLC ADR.

Receive notifications about Achilles Therapeutics PLC ADR in your mailbox!